Previous Close | 2.3000 |
Open | 2.3600 |
Bid | 2.3100 x 800 |
Ask | 2.4500 x 800 |
Day's Range | 2.2200 - 2.3800 |
52 Week Range | 1.8800 - 6.1400 |
Volume | |
Avg. Volume | 131,866 |
Market Cap | 101.474M |
Beta (5Y Monthly) | 1.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8600 |
Earnings Date | May 15, 2023 - May 19, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Aug 28, 1996 |
1y Target Est | 10.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for CVM
VIENNA, Va., March 08, 2023--CEL-SCI’s Multikine Phase 3 cancer study shows 43% survival extension.
VIENNA, Va., March 03, 2023--CEL-SCI to present new Phase 3 data at European Congress on Head & Neck Oncology.
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT First Quarter Fiscal Year 2023 Update CEL-SCI Corporation (NYSE:CVM) reported first quarter fiscal year 2023 results on February 15, 2023 and filed its Form 10-Q with the SEC. The company has continued to compile the clinical documentation necessary to support a Biologic License Application (BLA), which will be submitted in